|
Post-renovation BioPort Production
FDA Lot-Release
Authorizations
These memos show the authority for the manufacturer to
release anthrax vaccine from the manufacturing plant. Each lot of every vaccine
produced in the United States must be individually released in this way, after
having been tested for sterility, purity, potency, and general safety.
Lot-release tests are performed by the manufacturer and audited by FDA.
|
|
FAV114 PDF 17 Mar 05 | FAV113 PDF 22 Feb 05 | FAV112 PDF 15 Feb 05 | FAV111 PDF 17 Mar 05 | FAV110 PDF 30 Dec 04 |
�more...��*For Anthrax vaccine released after January 2002 (Lots FAV063 and higher)
|
|
|
|
|